Roanna Ruiz
Stock Analyst at Leerink Partners
(0.85)
# 3,926
Out of 5,182 analysts
60
Total ratings
35%
Success rate
-16.08%
Average return
Main Sectors:
Stocks Rated by Roanna Ruiz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYTK Cytokinetics | Maintains: Outperform | $83 → $84 | $61.60 | +36.36% | 2 | Feb 26, 2026 | |
| IBIO iBio, Inc. | Initiates: Outperform | $2 | $1.71 | +16.96% | 1 | Oct 17, 2025 | |
| XERS Xeris Biopharma Holdings | Maintains: Outperform | $7 → $9 | $6.12 | +47.06% | 7 | Aug 19, 2025 | |
| AKBA Akebia Therapeutics | Initiates: Outperform | $7 | $1.42 | +392.96% | 1 | Apr 28, 2025 | |
| CRMD CorMedix | Initiates: Outperform | $18 | $7.82 | +130.18% | 1 | Mar 7, 2025 | |
| LXRX Lexicon Pharmaceuticals | Downgrades: Market Perform | $1 | $1.69 | -40.83% | 1 | Mar 4, 2025 | |
| VIR Vir Biotechnology | Maintains: Outperform | $18 → $20 | $10.64 | +87.97% | 4 | Jan 13, 2025 | |
| SPRY ARS Pharmaceuticals | Maintains: Outperform | $26 → $27 | $7.95 | +239.62% | 4 | Jan 13, 2025 | |
| AQST Aquestive Therapeutics | Maintains: Outperform | $12 → $13 | $4.10 | +217.07% | 3 | Oct 25, 2024 | |
| ARDX Ardelyx | Initiates: Outperform | $14 | $5.99 | +133.72% | 1 | Apr 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $330 | $566.99 | -41.80% | 1 | Feb 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $25 | $46.22 | -45.91% | 1 | Apr 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | $49 | $13.28 | +268.98% | 10 | Feb 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $8 → $6 | $5.36 | +11.94% | 6 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $30.45 | -37.60% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $110 → $120 | $84.11 | +42.67% | 3 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $75 → $50 | $6.43 | +677.60% | 7 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $60 → $40 | $13.93 | +187.15% | 6 | Oct 19, 2022 |
Cytokinetics
Feb 26, 2026
Maintains: Outperform
Price Target: $83 → $84
Current: $61.60
Upside: +36.36%
iBio, Inc.
Oct 17, 2025
Initiates: Outperform
Price Target: $2
Current: $1.71
Upside: +16.96%
Xeris Biopharma Holdings
Aug 19, 2025
Maintains: Outperform
Price Target: $7 → $9
Current: $6.12
Upside: +47.06%
Akebia Therapeutics
Apr 28, 2025
Initiates: Outperform
Price Target: $7
Current: $1.42
Upside: +392.96%
CorMedix
Mar 7, 2025
Initiates: Outperform
Price Target: $18
Current: $7.82
Upside: +130.18%
Lexicon Pharmaceuticals
Mar 4, 2025
Downgrades: Market Perform
Price Target: $1
Current: $1.69
Upside: -40.83%
Vir Biotechnology
Jan 13, 2025
Maintains: Outperform
Price Target: $18 → $20
Current: $10.64
Upside: +87.97%
ARS Pharmaceuticals
Jan 13, 2025
Maintains: Outperform
Price Target: $26 → $27
Current: $7.95
Upside: +239.62%
Aquestive Therapeutics
Oct 25, 2024
Maintains: Outperform
Price Target: $12 → $13
Current: $4.10
Upside: +217.07%
Ardelyx
Apr 5, 2024
Initiates: Outperform
Price Target: $14
Current: $5.99
Upside: +133.72%
Feb 5, 2024
Initiates: Outperform
Price Target: $330
Current: $566.99
Upside: -41.80%
Apr 11, 2023
Initiates: Market Perform
Price Target: $25
Current: $46.22
Upside: -45.91%
Feb 9, 2023
Reiterates: Market Perform
Price Target: $49
Current: $13.28
Upside: +268.98%
Jan 27, 2023
Maintains: Market Perform
Price Target: $8 → $6
Current: $5.36
Upside: +11.94%
Dec 20, 2022
Initiates: Outperform
Price Target: $19
Current: $30.45
Upside: -37.60%
Nov 15, 2022
Maintains: Outperform
Price Target: $110 → $120
Current: $84.11
Upside: +42.67%
Nov 3, 2022
Maintains: Market Perform
Price Target: $75 → $50
Current: $6.43
Upside: +677.60%
Oct 19, 2022
Maintains: Market Perform
Price Target: $60 → $40
Current: $13.93
Upside: +187.15%